title: [Molecular targeted therapy for renal cell carcinoma].
abstract: Renal cell carcinoma (RCC) accounts for approximately 2% of all cancer cases worldwide. Metastatic disease is often present at the time of diagnosis of RCC and its poor response to chemotherapy and radiotherapy causes poor prognosis. Immunotherapy is relatively effective for RCC, but the response rate is approximately 15-20%. Therefore, new therapeutic approaches are necessary for these patients with metastatic RCC. Recently, the mechanisms responsible for the growth of RCC have been clarified, and molecular targeted therapy has been developed. In this paper, we review the new molecular targeted therapeutic agents effective for RCC.
authors.affiliation: Department of Urology, Kyoto Prefectural University of Medicine.
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Mizutani
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Nakanishi
authors.forename: Masaaki
authors.initials: M
authors.lastname: Mizuno
authors.forename: Jun
authors.initials: J
authors.lastname: Yoshida
authors.forename: Tsuneharu
authors.initials: T
authors.lastname: Miki
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D051017:Apoptosis Regulatory Proteins; D001557:Benzenesulfonates / Q000008:administration & dosage; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D016503:Drug Delivery Systems; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D016899:Interferon-beta / Q000008:administration & dosage; D047908:Intracellular Signaling Peptides and Proteins / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008081:Liposomes; D024101:Mitochondrial Proteins / Q000008:administration & dosage; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage; D011758:Pyrroles / Q000008:administration & dosage; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077157:Sorafenib; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; D001557:Benzenesulfonates; C412403:DIABLO protein, human; D007211:Indoles; D047908:Intracellular Signaling Peptides and Proteins; D008081:Liposomes; D024101:Mitochondrial Proteins; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; C401859:temsirolimus; D016899:Interferon-beta; D000077157:Sorafenib; D000077210:Sunitinib; D020123:Sirolimus